Leblond, V. Et Al. 2018. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. HAEMATOLOGICA , vol.103, no.11 , 1889-1898.

Leblond, V., Aktan, M., Ferra Coll, C. M., Dartigeas, C., Kisro, J., Montillo, M., ... Raposo, J.(2018). Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study. HAEMATOLOGICA , vol.103, no.11, 1889-1898.

Leblond, Veronique Et Al. "Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study," HAEMATOLOGICA , vol.103, no.11, 1889-1898, 2018

Leblond, Veronique Et Al. "Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study." HAEMATOLOGICA , vol.103, no.11, pp.1889-1898, 2018

Leblond, V. Et Al. (2018) . "Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study." HAEMATOLOGICA , vol.103, no.11, pp.1889-1898.

@article{article, author={Veronique Leblond Et Al. }, title={Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study}, journal={HAEMATOLOGICA}, year=2018, pages={1889-1898} }